IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
IQV - IQVIA Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$246.13
DETAILS
HIGH:
$287.00
LOW:
$185.00
MEDIAN:
$243.50
CONSENSUS:
$246.13
DOWNSIDE:
7.62%
Stock News
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Arizona State Retirement System Buys 2,372 Shares of IQVIA Holdings Inc. $IQV
Arizona State Retirement System lifted its stake in IQVIA Holdings Inc. (NYSE: IQV) by 5.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,655 shares of the medical research company's stock after purchasing an additional 2,372 shares during the quarter. Arizona
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and e.
IQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. (âIQVIAâ) (NYSE: IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the âIssuerâ), intends to raise $2,000,000,000 th
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses relate.
B. Metzler seel. Sohn & Co. AG Lowers Holdings in IQVIA Holdings Inc. $IQV
B. Metzler seel. Sohn and Co. AG cut its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 28.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,610 shares of the medical research company's stock after selling 9,713 shares
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical.
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial executio.
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.
Callan Family Office LLC Invests $1.75 Million in IQVIA Holdings Inc. $IQV
Callan Family Office LLC bought a new position in IQVIA Holdings Inc. (NYSE: IQV) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,044 shares of the medical research company's stock, valued at approximately $1,747,000. Other hedge funds and other
IQVIA (NYSE:IQV) versus BioLife Solutions (NASDAQ:BLFS) Head to Head Review
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and IQVIA (NYSE: IQV - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Valuation and Earnings This table compares BioLife Solutions and
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing proble.
BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV
BlackRock Inc. bought a new position in IQVIA Holdings Inc. (NYSE: IQV) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 14,549,693 shares of the medical research company's stock, valued at approximately $2,811,292,000. BlackRock Inc. owned about 8.84% of
Bruni J V & Co. Co. Purchases New Shares in IQVIA Holdings Inc. $IQV
Bruni J V and Co. Co. purchased a new position in IQVIA Holdings Inc. (NYSE: IQV) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 66,918 shares of the medical research company's stock, valued at approximately $12,929,896,000. IQVIA accounts for about
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology cover.
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Price Targets
Iqvia price target raised to $270 from $240 at Morgan Stanley
$270.00
(was $268.82)
Morgan Stanley
Iqvia price target raised to $247 from $221 at RBC Capital
$247.00
(was $246.03)
RBC Capital
Iqvia price target raised to $270 from $210 at BMO Capital
$270.00
(was $249.51)
Sean Dodge
·
BMO Capital
Iqvia price target raised to $287 from $252 at Baird
$287.00
(was $243.31)
Eric Coldwell
·
Robert W. Baird
Iqvia price target raised to $230 from $215 at Mizuho
$230.00
(was $207.85)
Ann Hynes
·
Mizuho Securities
Iqvia named short-term buy idea at Deutsche Bank
$240.00
(was $208.00)
Deutsche Bank
Iqvia price target raised to $240 from $210 at HSBC
$240.00
(was $206.42)
Sidharth Sahoo
·
HSBC
Iqvia price target raised to $249 from $230 at Baird
$249.00
(was $193.22)
Robert W. Baird
Iqvia downgraded to Equal Weight from Overweight at Morgan Stanley
$200.00
(was $179.17)
Kallum Titchmarsh
·
Morgan Stanley
Iqvia price target lowered to $210 from $240 at HSBC
$210.00
(was $180.64)
HSBC
Iqvia price target lowered to $225 from $240 at Morgan Stanley
$225.00
(was $179.31)
Morgan Stanley
Iqvia price target lowered to $185 from $225 at Evercore ISI
$185.00
(was $172.54)
Elizabeth Anderson
·
Evercore ISI
Iqvia price target lowered to $215 from $266 at Mizuho
$215.00
(was $165.62)
Mizuho Securities
Iqvia price target lowered to $245 from $290 at Truist
$245.00
(was $165.64)
Truist Financial
Iqvia price target lowered to $240 from $265 at Morgan Stanley
$240.00
(was $178.88)
Morgan Stanley
Iqvia price target lowered to $240 from $280 at UBS
$240.00
(was $184.01)
UBS
Iqvia price target lowered to $250 from $260 at BMO Capital
$250.00
(was $184.75)
BMO Capital
Iqvia price target lowered to $220 from $273 at Stifel
$220.00
(was $184.67)
Stifel Nicolaus
Iqvia price target lowered to $210 from $230 at Barclays
$210.00
(was $180.96)
Luke Sergott
·
Barclays
IQVIA Holdings (IQV) PT Lowered to $225 at Evercore ISI
$225.00
(was $180.96)
Elizabeth Anderson
·
Evercore ISI